Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer

Tunicamycin as a Novel Redifferentiation Agent in Radioiodine Therapy for Anaplastic Thyroid Cancer

The silencing of thyroid-related genes presents difficulties in radioiodine therapy for anaplastic thyroid cancers (ATCs). Tunicamycin (TM), an N-linked glycosylation inhibitor, is an anticancer drug. Herein, we investigated TM-induced restoration of responsiveness to radioiodine therapy in radioiod...

Full description

Bibliographic Details
Main Authors: Yoon Ju Choi, Jae-Eon Lee, Hyun Dong Ji, Bo-Ra Lee, Sang Bong Lee, Kil Soo Kim, In-Kyu Lee, Jungwook Chin, Sung Jin Cho, Jaetae Lee, Sang-Woo Lee, Jeoung-Hee Ha, Yong Hyun Jeon
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:International Journal of Molecular Sciences
Subjects:
tunicamycin
sodium-iodide symporter
anaplastic thyroid cancer
redifferentiation
radioiodine therapy
Online Access:https://www.mdpi.com/1422-0067/22/3/1077

Internet

https://www.mdpi.com/1422-0067/22/3/1077

Similar Items